Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLP-HPV-01
- Development stage
- Phase 2
- Lead developer
- ISA Pharmaceuticals
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal, Subcutaneous
01
Overview
SLP-HPV-01 is a therapeutic cancer vaccine composed of synthetic long peptides derived from human papillomavirus type 16 (HPV16) oncoproteins E6 and E7, designed to induce robust HPV16-specific T-cell responses against HPV-driven premalignant and malignant lesions. It consists of two drug products: HPV-DP-7P (seven E6 peptides) and HPV-DP-6P (E7 peptides), delivered intradermally, and has shown safety, immunogenicity, and clinical activity in HPV16-positive intraepithelial neoplasias and cancers, including dose-dependent immune responses and lesion regression in HIV-positive men with HPV16-positive high-grade anal intraepithelial neoplasia and high response rates previously reported in vulvar intraepithelial neoplasia. Developed by ISA Pharmaceuticals, with clinical collaborations including academic centers and industry partners in later programs under related identifiers (e.g., peltopepimut-S/ISA-101).[5][1][3][9]
- Brand names
- SLP-HPV-01SLP-HPV01SLP-HPV 01
- Other names
- synthetic long E6/E7 peptides vaccine HPV-01HPV-16 E6/E7 synthetic long peptides vaccine
02
Targets
Human papillomavirus type 16 E6/E7-derived peptide–Human leukocyte antigen complexesHPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on SLP-HPV-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLP-HPV-01.